Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 288.00
Bid: 284.00
Ask: 287.00
Change: 1.00 (0.35%)
Spread: 3.00 (1.056%)
Open: 281.00
High: 288.00
Low: 280.00
Prev. Close: 287.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Shareholder Meetings Calendar - Next 7 Days

Fri, 20th Apr 2018 15:00

Monday 23 April
Foreign & Colonial Investment Trust 
Bioquell
Microgen
HgCapital Trust
Silence Therapeutics
Tuesday 24 April
Shire
Hammerson
Metro Bank
London Stock Exchange Group
Tribal Group
Alfa Financial Software Holdings
UK Oil & Gas Investments
Wednesday 25 April
Drax Group
British American Tobacco
CLS Holdings
Croda International
Devro
Mithras Investment Trust
Nichols 
Personal Group Holdings 
Polar Capital Global Financials Trust 
Tullow Oil
Countrywide 
EP Global Opportunities Trust
Persimmon
intu properties 
BlackRock World Mining Trust
Polymetal International
Thursday 26 April
CRH
Sthree
Elementis
Murray International Trust
STV Group 
Admiral Group
Fidessa Group
French Connection Group
Just Eat 
Aggreko
Cobham
FDM Group 
LSL Property Services
Meggitt
RIT Capital Partners
Schroders
SDL 
Synthomer 
Taylor Wimpey
Weir Group
Friday 27 April 
Rotork
Ultra Electronics Holdings
Travis Perkins
Merlin Entertainments
LMS Capital
Laird
Hutchison China Meditech
Senior
 

More News
9 Aug 2021 12:35

Hutchmed strikes collaboration deal with Epizyme

(Sharecast News) - Commercial-stage biotechnology company Hutchmed China announced a collaboration to research, develop, manufacture and commercialise 'Tazverik' in Greater China on Monday, including mainland China, Hong Kong, Macau and Taiwan.

Read more
9 Aug 2021 10:06

Hutchmed to partner with Epizyme on tumour-targetting treatment

Hutchmed to partner with Epizyme on tumour-targetting treatment

Read more
28 Jul 2021 14:51

Hutchmed research costs deepen loss; expects US launches in 2022, 2023

Hutchmed research costs deepen loss; expects US launches in 2022, 2023

Read more
28 Jul 2021 11:33

IN BRIEF: Hutchmed and AstraZeneca launch phase two cancer med trial

IN BRIEF: Hutchmed and AstraZeneca launch phase two cancer med trial

Read more
28 Jul 2021 10:58

AIM WINNERS & LOSERS: Hutchmed notes phase 2 trial; Tricorn drops 25%

AIM WINNERS & LOSERS: Hutchmed notes phase 2 trial; Tricorn drops 25%

Read more
21 Jul 2021 16:12

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
16 Jul 2021 11:19

AIM WINNERS & LOSERS: Pantheon up on resource upgrade, farmout talks

AIM WINNERS & LOSERS: Pantheon up on resource upgrade, farmout talks

Read more
16 Jul 2021 10:55

IN BRIEF: Hutchmed tumor drug qualifies for formal review by EU agency

IN BRIEF: Hutchmed tumor drug qualifies for formal review by EU agency

Read more
13 Jul 2021 15:42

Hutchmed makes first commercial sale of 'Orpathys' in China

(Sharecast News) - Hutchmed China announced the first commercial sale in China of 'Orpathys', or savolitinib, on Tuesday, which is its "oral, potent, and highly-selective" small molecule inhibitor of MET, a receptor tyrosine kinase.

Read more
13 Jul 2021 14:06

TRADING UPDATES: Smiths gets Euros sticker boost; Hotel Chocolat grows

TRADING UPDATES: Smiths gets Euros sticker boost; Hotel Chocolat grows

Read more
6 Jul 2021 20:38

TRADING UPDATES: Hipgnosis placing oversubscribed; Creightons delays

TRADING UPDATES: Hipgnosis placing oversubscribed; Creightons delays

Read more
1 Jul 2021 19:26

TRADING UPDATES: Gym Group bulks up with placing; 88 Energy debt free

TRADING UPDATES: Gym Group bulks up with placing; 88 Energy debt free

Read more
30 Jun 2021 19:14

TRADING UPDATES: Topps Tiles improves as curbs ease; Bermele makes buy

TRADING UPDATES: Topps Tiles improves as curbs ease; Bermele makes buy

Read more
23 Jun 2021 18:10

IN BRIEF: Hutchmed launches global offering for 104 million shares

IN BRIEF: Hutchmed launches global offering for 104 million shares

Read more
22 Jun 2021 20:16

IN BRIEF: Hutchmed lung cancer treatment savolitinib approved in China

IN BRIEF: Hutchmed lung cancer treatment savolitinib approved in China

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.